[go: up one dir, main page]

MX2018015871A - Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. - Google Patents

Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.

Info

Publication number
MX2018015871A
MX2018015871A MX2018015871A MX2018015871A MX2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A MX 2018015871 A MX2018015871 A MX 2018015871A
Authority
MX
Mexico
Prior art keywords
cenicriviroc
purified
intermediates
making
high purity
Prior art date
Application number
MX2018015871A
Other languages
English (en)
Inventor
Morra Nicholas
Phiasivongsa Pasit
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MX2018015871A publication Critical patent/MX2018015871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
    • B01J31/223—At least two oxygen atoms present in one at least bidentate or bridging ligand
    • B01J31/2239—Bridging ligands, e.g. OAc in Cr2(OAc)4, Pt4(OAc)8 or dicarboxylate ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
    • B01J2231/4211—Suzuki-type, i.e. RY + R'B(OR)2, in which R, R' are optionally substituted alkyl, alkenyl, aryl, acyl and Y is the leaving group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Detergent Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

La descripción incluye compuestos de alta pureza que tienen antagonismo a CCR5 y/o CCR2, o sales de estos, intermedios pureza alta de estos y procesos para sintetizarlos.
MX2018015871A 2016-06-21 2017-06-21 Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. MX2018015871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352885P 2016-06-21 2016-06-21
PCT/US2017/038460 WO2017223155A1 (en) 2016-06-21 2017-06-21 Purified cenicriviroc and purified intermediates for making cenicriviroc

Publications (1)

Publication Number Publication Date
MX2018015871A true MX2018015871A (es) 2019-08-14

Family

ID=60661588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015871A MX2018015871A (es) 2016-06-21 2017-06-21 Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.

Country Status (13)

Country Link
US (3) US10407411B2 (es)
EP (1) EP3471718A4 (es)
JP (1) JP2019520427A (es)
KR (1) KR20190039087A (es)
CN (1) CN109862890A (es)
AU (1) AU2017280068A1 (es)
BR (1) BR112018076449A2 (es)
CA (1) CA3028151A1 (es)
IL (1) IL263789A (es)
MX (1) MX2018015871A (es)
RU (1) RU2019101242A (es)
SG (1) SG11201811140UA (es)
WO (1) WO2017223155A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
CA2304959A1 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
US6096780A (en) 1998-08-20 2000-08-01 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use
WO2001017947A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
DK2206702T3 (da) 2001-08-08 2012-02-13 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
US20050107606A1 (en) 2002-03-12 2005-05-19 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
US20080249147A1 (en) 2004-03-24 2008-10-09 Takeda Pharmaceutical Company Limited Emulsion-Stabilized Preparation
CA2560298A1 (en) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Preparation with elevated content
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
WO2006059716A1 (ja) 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited 固形製剤
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
KR101639095B1 (ko) * 2009-01-23 2016-07-12 스미또모 가가꾸 가부시키가이샤 공역 방향족 화합물의 제조 방법
SG190829A1 (en) 2010-11-18 2013-07-31 Univ Yale Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
CN105263498B (zh) * 2013-05-15 2019-04-26 妥必徕疗治公司 赛尼克韦罗组合物及其制备和使用方法
JP2016519166A (ja) * 2013-05-24 2016-06-30 クーパー ヒューマン システムズ エルエルシー Ｈｉｖ感染症を処置するための方法および組成物
US20170239262A1 (en) 2014-03-21 2017-08-24 Tobira Therapeutics ,Inc. Cenicriviroc for the treatment of fibrosis
RU2723559C2 (ru) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
BR112017013130A2 (pt) 2014-12-23 2017-12-26 Tobira Therapeutics Inc processo de fabricação de cenicriviroc e análogos relacionados
MX2017010277A (es) 2015-02-10 2017-12-07 Tobira Therapeutics Inc Cenicriviroc para el tratamiento de la fibrosis.

Also Published As

Publication number Publication date
CN109862890A (zh) 2019-06-07
AU2017280068A1 (en) 2019-01-31
US10407411B2 (en) 2019-09-10
KR20190039087A (ko) 2019-04-10
EP3471718A4 (en) 2020-01-08
CA3028151A1 (en) 2017-12-28
WO2017223155A1 (en) 2017-12-28
US20200095229A1 (en) 2020-03-26
RU2019101242A (ru) 2020-07-21
US20210171504A1 (en) 2021-06-10
SG11201811140UA (en) 2019-01-30
EP3471718A1 (en) 2019-04-24
BR112018076449A2 (pt) 2019-04-09
IL263789A (en) 2019-02-28
RU2019101242A3 (es) 2020-07-21
JP2019520427A (ja) 2019-07-18
US20170362207A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
EP4585268A3 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12017501825B1 (en) Bicyclic quinazolinone derivatives
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2020013849A (es) Nuevos compuestos de sulfonilaminobenzamida como antihelminticos.
MY188420A (en) Crystalline forms of (s)-afoxolaner
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
SG10201908248PA (en) Processes for preparing fluoroketolides
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
WO2015111085A8 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2018015871A (es) Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
AU2019248350A8 (en) Process for making sarecycline hydrochloride
TN2017000065A1 (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
WO2020128020A3 (de) Verfahren zur herstellung von 2-alkoxy-4-amino-5-methyl-pyridinen und/oder von 2-alkoxy-4-alkylamino-5-methyl-pyridinen